{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:16:33Z","timestamp":1782890193135,"version":"3.54.5"},"reference-count":30,"publisher":"Impact Journals, LLC","issue":"51","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,10,24]]},"DOI":"10.18632\/oncotarget.19382","type":"journal-article","created":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T02:06:15Z","timestamp":1500516375000},"page":"89364-89374","source":"Crossref","is-referenced-by-count":12,"title":["Aliskiren therapy in hypertension and cardiovascular disease: a systematic review and a meta-analysis"],"prefix":"10.18632","volume":"8","author":[{"given":"Shufang","family":"Fu","sequence":"first","affiliation":[{"name":"Medical Center of The Graduate School, Nanchang University, Nanchang, China"},{"name":"Department of Nephrology, The Second Affiliated Hospital of Nanchang University, Nanchang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wen","sequence":"additional","affiliation":[{"name":"Grade 2013, School of Stomatology, Nanchang University, Nanchang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Han","sequence":"additional","affiliation":[{"name":"Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Long","sequence":"additional","affiliation":[{"name":"Grade 2013, The Second Clinical Medical College of Nanchang University, Nanchang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaosi","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second Affiliated Hospital of Nanchang University, Nanchang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,7,19]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report","volume":"289","author":"Roccella","year":"2003","journal-title":"JAMA"},{"key":"2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria","volume":"354","author":"Remuzzi","year":"1999","journal-title":"Lancet"},{"key":"3","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(00)02212-1","article-title":"Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients","volume":"355","author":"Braunwald","year":"2000","journal-title":"Lancet"},{"key":"4","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(03)14739-3","article-title":"Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials","volume":"362","author":"Turnbull","year":"2003","journal-title":"Lancet"},{"key":"5","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1161\/ATVBAHA.108.164210","article-title":"Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells","volume":"28","author":"Danser","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"6","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Pfeffer","year":"2012","journal-title":"N Engl J Med"},{"key":"7","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1001\/jama.2013.1954","article-title":"Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial","volume":"309","author":"Lesogor","year":"2013","journal-title":"JAMA"},{"key":"8","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1001\/jama.2013.277169","article-title":"Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial","volume":"310","author":"Uno","year":"2013","journal-title":"JAMA"},{"key":"9","first-page":"702","article-title":"Aliskiren, Enalapril, or Both in Heart Failure","volume":"375","author":"K\u00f8ber","year":"2016","journal-title":"N Engl J Med"},{"key":"10","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jash.2007.04.004","article-title":"Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis","volume":"1","author":"Satlin","year":"2007","journal-title":"J Am Soc Hypertens"},{"key":"11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/1470320310381912","article-title":"A systematic review and meta-analysis of aliskiren and angiotension receptor blockers in the management of essential hypertension","volume":"12","author":"Lin","year":"2011","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"12","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1751-7176.2010.00352.x","article-title":"Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension","volume":"12","author":"Keefe","year":"2010","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"13","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1136\/bmj.e42","article-title":"The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis","volume":"344","author":"Shah","year":"2012","journal-title":"BMJ"},{"key":"14","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/11591970-000000000-00000","article-title":"Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan\/HCT combination: a placebo-controlled study","volume":"11","author":"Keefe","year":"2011","journal-title":"Am J Cardiovasc Drugs"},{"key":"15","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1161\/CIRCULATIONAHA.108.826214","article-title":"Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy","volume":"119","author":"Dahl\u00f6f","year":"2009","journal-title":"Circulation"},{"key":"16","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1751-7176.2009.00114.x","article-title":"Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone","volume":"11","author":"Zhang","year":"2009","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(07)61124-6","article-title":"Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial","volume":"370","author":"Satlin","year":"2007","journal-title":"Lancet"},{"key":"18","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1007\/s12325-008-0123-x","article-title":"Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study","volume":"25","author":"Zhang","year":"2008","journal-title":"Adv Ther"},{"key":"19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.amjhyper.2006.06.003","article-title":"Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan","volume":"20","author":"Satlin","year":"2007","journal-title":"Am J Hypertens"},{"key":"20","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/eurheartj\/ehq190","article-title":"Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial","volume":"31","author":"Cannon","year":"2010","journal-title":"Eur Heart J"},{"key":"21","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/jch.12032","article-title":"Randomized study of antihypertensive efficacy and safety of combination aliskiren\/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus","volume":"15","author":"Sowers","year":"2013","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"22","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/eurheartj\/ehq522","article-title":"Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction","volume":"32","author":"Pfeffer","year":"2011","journal-title":"Eur Heart J"},{"key":"23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIRCHEARTFAILURE.107.740704","article-title":"Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure","volume":"1","author":"Lewsey","year":"2008","journal-title":"Circ Heart Fail"},{"key":"24","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3317\/jraas.2007.028","article-title":"Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension","volume":"8","author":"Satlin","year":"2007","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"25","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/nrneph.2012.62","article-title":"RAS blockade, hyperkalemia and AKI\u2014look and you will find","volume":"8","author":"Toto","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"26","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1161\/HYPERTENSIONAHA.105.063636","article-title":"Kidney in hypertension: guyton redux","volume":"51","author":"Crowley","year":"2008","journal-title":"Hypertension"},{"key":"27","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7326\/0003-4819-115-7-513","article-title":"Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis","volume":"115","author":"Pettinger","year":"1991","journal-title":"Ann Intern Med"},{"key":"28","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Hollenberg","year":"2008","journal-title":"N Engl J Med"},{"key":"29","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dc09-0168","article-title":"Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria","volume":"32","author":"Parving","year":"2009","journal-title":"Diabetes Care"},{"key":"30","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.19382","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T17:11:14Z","timestamp":1596733874000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.19382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,19]]},"references-count":30,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2017,10,24]]}},"alternative-id":["19382","29179525"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.19382","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,19]]}}}